Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heat therapy could ease Dupuytren's contracture without surgery

NCT ID NCT07443371

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether TECAR therapy, a type of energy-based heat treatment, can reduce pain and improve hand movement in people with Dupuytren's contracture (palmar fibromatosis). Thirty-six adults aged 40 to 70 with mild to moderate finger contractures will receive 20-minute sessions. The goal is to see if this non-invasive approach can ease symptoms and improve daily hand function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transfer Energy Capacitive and Resistive (TECAR) therapy
What this could lead to
If it works, this could offer a non-surgical option to reduce pain and improve hand function for people with Dupuytren's contracture.
What could go wrong
This is a very small, early-stage trial with only 36 people. It may not show clear benefits, and results may not apply to everyone with the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages of patients will be ranged from 40 to 70 years. * Presence of palpable cords and/or digital contracture ≥ 20° at the metacarpophalengeal joint or Proximal interphalengeal joint joints . * Clinical diagnosis confirmed by a hand surgeon or relevant specialist. * All patients will enter the study having their informed consent Exclusion Criteria: * Patient with severe contracture \>30° or multiple digit involvement requiring surger. * History of surgical release (fasciotomy, fasciectomy) or collagenase injection in the affected hand. * Presence of infection, ulceration, or skin lesions on the treatment area. * Presence of pacemakers, metal implants, or other electronic implants in the treatment area. * Active cancer or tumor in the treatment region. * Pregnancy. * Conditions such as stroke, Parkinson's disease, or rheumatoid arthritis that may confound results. * Cognitive impairment, psychiatric illness, or other barriers to protocol adherence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Palmar fibromatosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palmar fibromatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Palmar fibromatosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peter Milad Haroun

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.